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Dietary sugars are linked to the development of non-alcoholic fatty liver disease (NAFLD) 
and dyslipidaemia, but it is unknown if NAFLD itself influences the effects of sugars on 
plasma lipoproteins. To study this further, men with NAFLD (n=11) and low liver fat 
‘controls’ (n= 14) were fed two iso-energetic diets, high or low in sugars (26% or 6% total 
energy) for 12 weeks, in a randomised, cross-over design. Fasting plasma lipid and 
lipoprotein kinetics were measured after each diet by stable isotope trace-labelling.   
There were significant differences in the production and catabolic rates of VLDL subclasses 
between men with NAFLD and controls, in response to the high and low sugar diets.  Men 
with NAFLD had higher plasma concentrations of VLDL1-triacylglycerol (TAG) after the 
high (P<0.02) and low sugar (P<0.0002) diets, a lower VLDL1-TAG fractional catabolic 
rate after the high sugar diet (P<0.01), and a higher VLDL1-TAG production rate after the 
low sugar diet (P<0.01), relative to controls. An effect of the high sugar diet, was to channel 
hepatic TAG into a higher production of VLDL1-TAG (P<0.02) in the controls, but in 
contrast, a higher production of VLDL2-TAG (P<0.05) in NAFLD. These dietary effects on 
VLDL subclass kinetics could be explained, in part, by differences in the contribution of 
fatty acids from intra-hepatic stores, and de novo lipogenesis. This study provides new 
evidence that liver fat accumulation leads to a differential partitioning of hepatic TAG into 
large and small VLDL subclasses, in response to high and low intakes of sugars.   
 
Summary Statement 
This study shows that raised liver fat can influence the effects of a high intake of sugars on 
lipid metabolism, and provides new evidence for a mechanism by which sugars could 
contribute to the development of non-alcoholic fatty liver disease (NAFLD). 
 
Clinical Trial Registration: NCT01790984 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is a common condition, defined histologically, 
as an excess of macro-vesicular steatosis (>5%) in the absence of a high intake of alcohol 
[1]. In addition to being a progenitor of end-terminal liver diseases, NAFLD has been linked 
to the metabolic syndrome, and is a potential source of elevated plasma TAG and 
abnormalities in plasma lipoproteins, known as an atherogenic lipoprotein phenotype (ALP) 
[2-4].  
Elevated plasma TAG promotes the development of an ALP through the extra-cellular  
remodelling of plasma low and high density lipoproteins (LDL and HDL) into small, dense 
particles with increased potential to promote atherosclerosis [5]. Plasma TAG may be raised 
by an overproduction of its principal transporter VLDL in the liver, and/or impaired 
clearance of VLDL from the plasma [6]. VLDL is secreted from the liver as a spectrum of 
particles that vary in size, composition and metabolic properties, which can be subdivided 
on the basis of hydrated density into two discrete subclasses of large, TAG-rich VLDL1 and 
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smaller VLDL2 (Svedberg flotation units (Sf) of 60-400 and 20-60, respectively) [7].  The 
particle size of VLDL in the liver in the fasted, post-absorptive state is largely determined 
by the availability of lipid in the form of non-esterifed fatty acids (NEFA) from peripheral 
adipose tissue (systemic source) or splanchnic sources, the latter of which includes visceral 
adipose tissue, intra-hepatic stores, and synthesis of fatty acids by de novo lipogenesis 
(DNL) in the liver [8].  
Free sugars in food and sugar-sweetened beverages have been implicated in the 
development of dyslipidaemia and NAFLD, either through the direct lipogenic effects of 
sugars on liver fat and VLDL metabolism, and/or via the indirect effects of the energy from 
sugars on body weight [9]. While DNL makes a relatively small contribution to VLDL-TAG 
production, this has been shown to increase substantially when a high proportion of dietary 
energy is supplied as sugars, especially sucrose and fructose (>20% total energy)[10].  
However, the extent to which liver fat affects the handling of hepatic fatty acids and alters 
VLDL metabolism in response to intakes of sugars representative of a Western diet, is 
currently unknown. This study tested the hypothesis that liver fat influences the metabolic 
effects of a high relative to a low intake of sugars (representative of the upper and lower 
2.5th percentiles of intake in the UK), on plasma lipoproteins, by altering the kinetics and 
source of fatty acids for the production of VLDL subclasses.  
 
MATERIAL AND METHODS 
Participants   
Participants were men (aged 40-65y, BMI 25-30) at increased cardio-metabolic risk, as 
determined by a 1 to 10 risk score used previously in the ‘RISCK’ study [11]. Men with a 
cardio-metabolic score of ≥4 and APO ε3/ε3 genotype (to exclude possible confounding 
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effects of different apo E isoforms on lipid metabolism), underwent an assessment of intra-
hepatocellular lipid (IHCL) by magnetic resonance spectroscopy (MRS) for assignment to a 
group with NAFLD  (>5.56%  IHCL, n=11) or low liver fat (Controls) (<5.56% IHCL, 
n=14) [12]. Exclusion criteria included diabetes and any medical condition other than 
NAFLD, lipid-lowering medication, unstable weight in the preceding 3 months, and an 
intake of alcohol exceeding 20g/day.  All participants provided written informed consent 
before taking part in the study, which received favourable ethical opinions from Surrey 
Research Ethics Committee (Ref. 08/H1109/227), and the University of Surrey’s Ethics 
Committee (Ref. EC/2009/29). The trial was registered on Clinical Trials.gov (Ref. 
NCT01790984).  
 
Study design  
The study had a randomised, two-way crossover design, with two 12 week dietary 
interventions. After an initial 4 week run-in period on their habitual diet, participants were 
randomised to either a high or low sugar diet, using a computer-generated sequence of 
treatments in sealed envelopes. The two diets were iso-energetic and contained the same 
macronutrient composition. Participants returned to their habitual diet for 4 weeks washout, 
before crossing-over to the alternative diet for a further 12 weeks.  During the dietary 
interventions, participants were instructed to maintain their habitual level of physical 
activity. Certain outcome measures were determined before and after each diet (body 
weight, percentage body fat, plasma lipids, glucose and serum insulin), while others were 
measured at the end of each diet (stable-isotope tracer kinetics, lipoprotein composition, 




Dietary interventions                  
Intakes of total carbohydrates and sugars were based on mean intakes for men aged 40-65 
years in the UK’s National Diet & Nutrition Survey (NDNS), with target intakes for non-
milk extrinsic sugars (NMES) on the high and low sugar diets corresponding to the upper 
and lower 2.5th percentile of intake in the UK population, respectively [13] . The term 
NMES, as originally defined by the UK’s Department of Health [14], included free sugars 
added to food (including 50% of sugars in tinned and dried fruit), but excluded sugars in 
whole fruit, and lactose, primarily from cows’ milk [15]. The content of sugars in the two 
diets was achieved by a dietary exchange of sugars for starch using a range of commercially 
available foods, as described in Supplementary Material. Dietary intakes were assessed by 
the completion of 3-day diet diaries during the final week of each dietary intervention (2 
weekdays and 1 weekend day). Diaries were analysed by a single operator using DietPlan 6 
(version 6.50, Forestfield Software Ltd, UK). 
Metabolic study (Post-diets)  
The study protocol is shown in Supplementary Figure 1. The evening before the metabolic 
study, participants consumed a set volume of deuterated water (2H2O 3g/kg body water; 
50% after a standardised low fat, low fibre meal (1900h) and 50% 3h later at 2200h). They 
then fasted and drank only water enriched with 2H2O (4.5g 2H2O/litre drinking water). The 
following morning, a blood sample was taken to measure deuterium enrichment of palmitate 
in VLDL1 and VLDL2-TAG, and plasma water to measure DNL (For calculation see 
Supplementary Material).  A primed, 10h constant iv [1-13C]leucine infusion (1mg/kg; 
1mg/kg/h) (99%, Cambridge Isotopes) was administered to measure VLDL1, VLDL2, IDL, 
LDL2 and LDL3-apoprotein B (apoB) kinetics.  An 8h constant iv infusion of [U-
13C]palmitate (99%, Cambridge Isotopes) bound to human albumin (5%, 0.01 µmol.kg-
1.min-1), was administered to measure palmitate production rate (PR, assumed to be mainly 
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from systemic adipose tissue lipolysis), and the percentage contribution of systemic NEFA 
to the export of TAG in VLDL1 and VLDL2. An intravenous bolus of [1,1,2,3,3-
2H5]glycerol (75µmol/kg) (99%, Cambridge Isotopes) was administered to measure VLDL1 
and VLDL2-TAG PR and fractional catabolic rate (FCR). Blood samples were taken at 
sequential time intervals to measure the isotopic enrichment and concentrations of plasma 
palmitate, αketoisocaproate (αKIC) and glycerol, and the enrichment and concentrations of 
apoB, TAG-palmitate and TAG-glycerol in the lipoprotein fractions, as reported previously 
[16, 17]. At the end of each dietary intervention period, the activity of lipoprotein lipase 
(LPL) and hepatic lipase (HL) in plasma was measured before and 15 minutes after an 
intravenous injection of 50U/kg heparin, as previously described [18]  
 
Magnetic resonance imaging (MRI) and spectroscopy (MRS) 
Whole body MRI scans were obtained on a 1.5T Phillips Achieva system (Philips Medical 
Systems, Best, The Netherlands). Volumes of intra-abdominal and subcutaneous abdominal 
adipose tissue were calculated from the abdominal region between the slices containing the 
bottom of the lungs/top of the liver, and femoral heads. Spectra were analysed by a single 
trained observer (ELT) using AMARES. Liver fat (IHCL) was measured relative to liver 
water content, as described previously [19].  Seventeen of the 25 participants who 




VLDL1, VLDL2, IDL, LDL2 and LDL3 were separated by sequential ultracentrifugation 
[7]. Plasma TAG, VLDL1 and VLDL2-TAG were extracted, and the isotopic enrichment of 
glycerol and TAG-palmitate in these extracts was measured by gas chromatography mass 
spectrometry (GCMS), as described previously [16]. The isotopic enrichment of leucine in 
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VLDL1, VLDL2 and IDL-apoB, and plasma αKIC enrichment, was measured by GCMS 
[17]. Leucine enrichment in LDL2 and LDL3-apoB was measured as the N-acetyl, n-propyl-
ester derivative and analyzed by GC-combustion isotope ratio MS (Delta plus XP isotope 
ratio MS, Thermo Scientific). Plasma 2H2O enrichment was measured with a Gasbench II 
inlet system and isotope ratio MS using platinum catalyst rods to liberate hydrogen gas. 
Isotopic enrichment was measured relative to laboratory standards, which had been 
previously calibrated against international standards; Vienna Standard Mean Ocean Water 
and Standard Light Arctic Precipitation (International Atomic Energy Agency, Vienna, 
Austria).  LPL and HL were measured in post-heparin plasma by the Confluolip Lipase test 
(Progen Biotechnik, Heidelberg). Plasma NEFA, total cholesterol, TAG, lipoprotein fraction 
TAG and cholesterol were measured by enzymatic assays using a Cobas MIRA (Roche, 
Welwyn Garden City, UK).  Apolipoprotein B (apo B) in lipoprotein fractions was 
measured by an in-house ELISA. Plasma apolipoproteins CII, CIII and E were measured by 
commercially available ELISAs (Biomedica, GmbH &Co Wien, Austria), and small dense 
(sd) LDL-cholesterol by a precipitation method (Randox Laboratories Ltd) on an ILab 650 
(Werfen). APO E genotype was determined by quantitative polymerase chain reaction and 
Southern blotting.  
 
Data analysis 
Tracer enrichment of αKIC, leucine, palmitate and glycerol was expressed as tracer/tracee 
ratio (TTR) corrected for baseline enrichment. Lipoprotein kinetics were analysed by 
compartmental modelling, as described previously  [16, 17]. These models and the 
calculation of the fatty acid contribution to VLDL-TAG PR, together with further details of 





Statistical methods  
Data are expressed as means (± SEM) for normally distributed variables, and log10 
transformed geometric means for non-normally distributed variables. 
Statistical modelling. Data are expressed as estimates of contrasts of least squares means for 
normally distributed variables, and as ratios of geometric means for logarithmically 
transformed variables. For outcome measures for which there were four samples from each 
participant (pre and post-diets, for each period), the post-diet measurements (NAFLD and 
controls for the 2-period cross-over, logarithmically transformed or not, as appropriate), 
were analysed as dependent variables in a general linear mixed model, with the following 
fixed categorical, non-random, explanatory effects: period, treatment (low and high sugar 
diet), period by treatment interaction (to detect carry-over effects), liver fat level (NAFLD 
and control) and treatment by liver fat level interaction. The pre-diet measurements 
(logarithmically transformed or not, as appropriate) for each period, and body weights (pre 
and post-diets) were included as covariates in the model, with participant as a model random 
effect.  For outcome measures for which there were two samples for each participant (post-
diets; end of each dietary intervention period only), each measurement for the combined 
groups (NAFLD and Controls), for the 2-period cross-over, were analysed in a general 
linear mixed model with the same fixed categorical effects as above, and body weights (pre 
and post-diets) as co-variates. Variables for which there was no significant carry-over effect, 
were modelled as above, omitting the period-by-treatment interaction from the model.  
There was only evidence of significant treatment by period interactions (carry-over effect) at 
the 5% level for VLDL1-TAG fractional catabolic rate, which was modelled using data from 
the first period only. Modelling was performed using procedure MIXED of SAS Version 9.2 





Twenty five men completed the study.  The baseline characteristics of the NAFLD and control 
groups, including age, body weight, BMI, waist circumference and biochemical measures, 
were similar, except for plasma TAG, which was 42% higher in men with NAFLD than 
controls (P<0.05, Table 1).  
Dietary intake and changes in body weight  
Self-recorded dietary intakes were monitored by regular visits to the homes of participants, 
and indicated that dietary compliance was maintained. There was no difference in reported 
energy intake between diets, or differences in energy intake, macronutrients or alcohol 
between NAFLD and controls on either diets (Supplementary Table 1). The high sugar 
diet resulted in a higher intake of total sugars and NMES (26% total energy) in comparison 
to the baseline and low sugar diet (6% total energy) in both men with NAFLD and controls 
(P<0.01 for all comparisons). The high sugar diet was also lower in starch (P<0.01) than the 
low sugar diet in both groups. Percent energy intake from dietary fat was significantly lower 
on the high sugar diet in controls (P<0.001). 
Body weight was higher after the high versus low sugar diet in NAFLD (P<0.001) and 
controls (P<0.01), with both groups gaining and losing approximately 2kg on the high and 
low sugar diets, respectively (Table 2). All variables were adjusted for these differences in 
body weight in the statistical analysis (see Statistical Methods). There was no significant 
difference in body weight between groups after either diet, or differences in the change of 
body weight between groups on either diet, over time.  
Plasma lipids and lipoprotein kinetics 
Summary of model interactions: There was an overall difference in the response to the 
two diets between the NAFLD and control groups, as evidenced by significant Group 
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(NAFLD vs control) x Diet (high vs low sugars) interactions for our primary outcome 
variables. These interactive variables included: 1) the plasma concentration and production 
rate of large, TAG-rich VLDL1-TAG (P = 0.026, P = 0.015), which were higher in NAFLD 
compared to controls, but which increased in the controls in response to the high sugar diet;       
2) the rate of VLDL2-TAG production (P = 0.04), which was higher in NAFLD than 
controls after the high sugar diet; 3) the rate of removal of plasma small, dense LDL3-apo B 
(P = 0.02), which was lower in NAFLD than controls after the low sugar diet; 4) plasma 
NEFA (P=0.004) which was higher in NAFLD than controls after the high sugar diet; and 
5) the contribution of DNL to VLDL1TAG production (P=0.02), which tended to be greater 
in controls after the high versus the low sugar diet, and higher in NAFLD relative to 
controls after the low sugar diet.     
Post-hoc differences between groups: Men with NAFLD had higher plasma concentration 
of total VLDL-TAG and VLDL1-TAG than controls, after the high (P<0.02 for both 
comparisons), and low (P<0.001, for both comparisons) sugar diets (Table 3, Figure 1a), 
and a higher VLDL1-TAG production rate and lower VLDL1-TAG FCR than controls, after 
the low and high sugar diets, respectively (Figure 1c, and Table 4, P=0.01 for both 
comparisons). Men with NAFLD also had a higher concentration of plasma small, dense 
LDL cholesterol (sdLDL), and lower FCR for small, dense LDL3-apo B than controls, after 
the low sugar diet (P<0.05 for both comparisons) (Tables 3 and 4). 
Post-hoc differences between diets: Men with NAFLD had a higher production rate of 
VLDL2-TAG (P=0.036, Table 4, Figure 1d) after the high versus the low sugar diet. In 
contrast, controls had a significantly higher production rate of VLDL1-TAG (P=0.02), and 
trend towards a higher plasma concentration of VLDL1-TAG (P=0.058), after the high 
versus low sugar diet (Figures 1c and 1a). Men with NAFLD had a higher plasma 
concentration of IDL-apo B (P=0.025, Table 3), IDL-apo B pool size (P=0.025, data not 
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shown), and trend for a higher IDL-apo B production rate (p=0.06, Table 4), after the high 
versus the low sugar diet.  
Sources of fatty acids for VLDL production  
Post-hoc differences between groups: Men with NAFLD had a greater contribution of 
fatty acids from splanchnic fat for the production of VLDL1 and VLDL2-TAG relative to 
controls, after the high sugars diet (Figures 1c & 1d,  P<0.05 for both comparisons). This 
group also expressed a greater contribution of fatty acids from splanchnc fat, and DNL for 
the production of VLDL1-TAG after the low sugars diet (Figure 1c, P=0.006, P=0.003, 
respectively), and a markedly higher plasma concentration of NEFA after the high sugars 
diet, relative to controls (P=0.0007, Table 5).   
Post-hoc differences between diets: There were no significant effects of diet on the source 
of fatty acids for VLDL production, other than a trend for a greater contribution from DNL 
to the production of VLDL1 and VLDL2-TAG in controls, after the high versus the low 
sugars diet (P=0.08 for both VLDL subclasses).  The production and metabolic clearance 
rates of palmitate were higher in men with NAFLD (P=0.025, P=0.006, respectively), after 
the high versus low sugars diet (Table 5). 
Plasma apoproteins and post-heparin lipase activities  
Post-hoc differences between groups: Men with NAFLD had a higher plasma apoprotein 
C-III than controls, after the high and low sugars diets (P=0.042, p=0.002, respectively), and 
a higher plasma apoprotein C-II than controls after the low sugars diet (P=0.033). The 
activity of hepatic lipase was higher in men with NAFLD versus controls after the high 
sugars diet (P<0.05) (Table 5).  
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Liver fat, intra-abdominal and subcutaneous adipose tissue (subgroup n=17, post-diet) 
Liver fat was higher after the high sugars diet in men with NAFLD and controls, relative to 
the low sugars diet (P=0.01 for both comparisons, Table 2).  However, the significance of 
these differences was not maintatined after adjustment for body weight. There were no 
differences in the masses of visceral and subcutaneous adipose tissue between groups after 
each diet. (Supplementary Table 3). There were also no associations between post-dietary 
liver fat, body weight, visceral fat, plasma TAG, or changes in these variables.  
 
DISCUSSION                                                                                                                                              
This study provides new evidence that liver fat can influence the weight-adjusted 
partitioning of hepatic TAG into different plasma VLDL subclasses, in response to a high 
intake of sugars that is common to the UK diet [13].  Men with NAFLD were distinct from 
controls in having a higher plasma and production rate of large, TAG-rich VLDL1, after 
both diets. This finding is consistent with the previous observation that VLDL1 
overproduction is driven by increased liver fat [20].  In the present study, this effect 
originated, in part, from a greater contribution of fatty acids from splanchnic fat (hepatic 
TAG storage pools, visceral fat, and to a lesser extent DNL in the liver). A highly original 
finding in this study, was that these metabolic characteristics in men with NAFLD were 
shown to develop in response to the high sugars diet in low liver fat controls. In contrast, the 
high sugars diet upregulated the production of VLDL2 in NAFLD relative to controls, a 
difference that was also ascribed to a greater contribution of splanchnic fatty acids for the 
production of this smaller VLDL subclass (Figure 2).    
Large TAG-rich VLDL1 has been associated with increased liver fat and dyslipidaemia in 
the metabolic syndrome [20, 21], but there is no previous evidence to link its plasma 
concentration or kinetics directly with a high intake of sugars in humans. There have also 
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been no studies to date on the effect of dietary free sugars on VLDL kinetics in NAFLD.    
In healthy subjects, the production rate of VLDL-TAG has been shown to be higher after a 
6-day hyper-energetic diet enriched with fructose as a liquid supplement (25% total energy) 
versus a 6-day, low-fructose diet [22]. VLDL-TAG production rate was also higher after a 
two-week high carbohydrate, low fat diet, compared to a two-week iso-energetic, low 
carbohydrate, high fat diet in healthy subjects [23].  In the present study, the production rate 
and plasma concentration of large, TAG-rich VLDL1 were higher in the low liver fat 
controls on the high sugars diet compared to the low sugars diet. Moreover, the difference in 
production rate of large TAG-rich VLDL1 between groups was removed on the high sugars 
diet, as the values in controls approached that of men with NAFLD, possibly because the 
controls also gained liver fat. In contrast, the production rate of smaller VLDL2-TAG was 
significantly higher in NAFLD after the high relative to the low sugar diet. Since VLDL2 is 
known to be the main precursor of IDL and LDL [24], this finding is consistent with an 
increase in IDL apoB production rate and the pool size of IDL apoB and plasma 
concentration of apoB in IDL, and sdLDL, both of which are components of an atherogenic 
lipoprotein phenotype [25]. Interestingly, there was no evidence in our study of any group or 
dietary effects on the production and secretion of new VLDL particles, as indicated by a 
lack of significant effects on plasma VLDL apoB or changes in the kinetics of VLDL-apoB.  
Men with NAFLD had a higher DNL relative to controls after the low sugars diet, in accord 
with previous reports of increased contribution of DNL to hepatic fat and dyslipidaemia in 
men with NAFLD [8, 26]. However, this finding was only significant on the low sugars diet, 
possibly because the contribution of DNL to both VLDL1 and VLDL2-TAG increased to a 
greater extent in controls than in men with NAFLD after the high sugars diet.  DNL made 
relatively minor contributions (between 4-8%) to VLDL1 and VLDL2-TAG production in 
both groups, after both diets, as reported previously in healthy subjects [27]. DNL has been 
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shown to contribute approximately 12% of palmitate to VLDL-TAG in a previous study in 
NAFLD, when measured over a comparable time period to the present study [8].  In a 
previous study, an 8 week diet with fructose-sweetened beverages, providing 25% of total 
energy, increased DNL, whereas glucose-sweetened beverages had no effect in the healthy 
overweight participants [28].  Similarly, a 6-day high-fructose diet (25% total energy) was 
shown to increase DNL from 1.6 to 9.4% in VLDL-palmitate in healthy, normal weight men 
[29].   
In the present study, there was no significant difference in the systemic contribution of fatty 
acids to VLDL1-TAG or VLDL2-TAG production between the diets in either groups. This 
is perhap surprising, given the marked increase in plasma NEFA and higher production and 
clearance rates of palmitate after the high sugars diet in the NAFLD group, which might be 
expected to increase the delivery of NEFA to the liver. There was, however, a greater 
contribution of splanchnic fat to VLDL1-TAG and VLDL2-TAG production in NAFLD 
relative to controls, which might help to explain how liver fat influences the differential 
partitioning of hepatic TAG in these groups in response to dietary sugars.  
Splanchnic fat includes hepatic TAG storage pools and visceral adipose tissue, the NEFA 
from which drains directly into the liver via the portal vein. Hepatic TAG storage pools will 
expand in the fed, postprandial state, with an estimated 22% of dietary TAG being taken-up 
by the liver in chylomicron remnants [30], some of which will be stored and contribute to 
VLDL synthesis in the post-absorptive state [31].  
The flux of NEFA from visceral adipose tissue has been estimated to be 20% of total NEFA 
delivery to the liver in obese subjects, but only 5% in lean subjects [32, 33] based on a 
model partially validated in dogs [34]. Visceral adipose NEFA flux was also shown to 




Since the men in our study were generally overweight, but not obese, visceral adipose tissue 
is likely to have made a small contribution (5-20%) towards the delivery of total NEFA to 
the liver [32, 33].  However, since visceral fat was not different between groups and 
unaffected by the diets in the present study, this suggests that the relatively greater 
contribution of splanchnic-derived NEFAs to VLDL1 and VLDL2-TAG production on the 
high sugars diet in NAFLD relative to controls, came from hepatic TAG storage pools.  This 
possibility introduces the established effect of dietary sugars in augmenting post-prandial 
lipaemia [35], and highlights the importance of postprandial TAG as a potential source of 
lipid for the accumulation of liver fat [36].  While postprandial responses were not measured 
in our study, the high sugar diet increased VLDL1 in controls, and serum apo C-III in 
NAFLD, an apoprotein with roles in the assembly of VLDL1 in the liver and inhibition of 
LPL [37]. These effects are consistent with dietary free sugars impairing the clearance of 
plasma TAG in the postprandial phase [35, 36].   
The intake of sugars on the low sugars diet was close to the current recommendation for the 
intake of free sugars, of no more than 5% total energy (NMES 6 ± 2% total energy or 586 kJ 
(140kcal) /day) [38, 39]. In contrast, the intake of sugars on the high sugars diet (NMES 26 
± 7% total energy) was five-fold greater than this recommendation (2,721kJ (650kcals) 
/day), but still within the upper 2.5th percentile of intake in a typical UK diet [13]. Although 
we cannot exclude the possibility that the small differences in the intake of dietary fat 
between the iso-energetic diets contributed to the metabolic effects (5% and 8% energy in 
NAFLD and controls, respectively), the overall, weight-adjusted response of outcome 
variables is consistent with the marked differences in intake of dietary sugars between the 
two diets (19% and 20% energy, in NAFLD and controls, respectively).  
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It is well documented that hyper-energetic diets, high in sugars, increase liver fat in healthy 
men [40], but there is less evidence that iso-energetic diets, high in sugars, exert the same 
effect. A weight-maintaining high fructose diet (25% total energy) has been reported to 
increase liver fat by 137% in healthy men [41]. Similarly, an iso-energetic diet containing 
sucrose-sweetened regular cola increased liver fat by 132% in overweight subjects [42]. In 
the present study, the high sugars diet increased liver fat to a relatively greater extent in 
subgroups of men with NAFLD, compared to controls. While this might suggest greater 
sensitivity to dietary sugars in NAFLD, the statistical significance of this difference in liver 
fat was lost after adjustment for the small gain in body weight. This finding reaffirms that 
liver fat is very sensitive to increased body weight in response to dietary sugars [43]. 
Strengths of our study include the dietary exchange, which achieved its targets for sugar 
intake in a free-living setting, and stable isotope trace-labelling methodology to 
simultaneously track the metabolism of plasma lipoproteins, fatty acids and DNL. 
Limitations of our study include its sample size and the dependence of our main outcomes 
measures on the assumptions inherent in mathematical modelling. In addition, results 
derived from the infusion of stable isotope labelled palmitate are dependent on the validity 
of assumptions regarding fatty acid fluxes to the liver. While we adjusted all data for the 
small and consistent changes in body weight in response to differences in energy intake 
between diets, we cannot exclude the possibility of acute metabolic effects arising from 
these differences. Nevertheless, the overall pattern of metabolic responses to the diets, and 
significance of weight-adjusted differences in our outcome variables, including VLDL1-
TAG production rate, on which the sample size was originally powered, provide confidence 
that the data is robust. It also suggests that the effects of a high and low intake of sugars on 
lipoprotein metabolism were independent of the relationship between changes in body 
weight and liver fat.   
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This study provides new evidence that liver fat influences the effects of dietary free sugars 
in partitioning plasma TAG into different VLDL subclasses.  This finding has major 
implications for the potential mechanism by which dietary free sugars could contribute to 
the development of NAFLD, and dyslipidaemia.    
 
CLINCAL PERSPECTIVES  
• A high intake of dietary sugars consumed in foods and sugar sweetened beverages, has 
been implicated in the development of fatty liver disease, possibly through adverse 
effects on lipid metabolism. This study was undertaken to determine if liver fat 
influences the plasma lipid and lipoprotein response to sugars, and the mechanism by 
which sugars contribute to the accumulation of liver fat.  
 
• High and low sugar diets produced differential effects on the metabolism of plasma 
VLDL subclasses in men with raised liver fat (NAFLD) and low liver fat controls. A 
high intake of sugars produced changes in the lipoprotein metabolism of controls that 
were characteristic of men with NAFLD.  
 
• These findings indicate that the accumulation of liver fat can influence the plasma lipid 
and lipoprotein response to dietary sugars, and provide new evidence for a mechanism 
to explain how sugars may contribute to NAFLD and dyslipidaemia.   
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                                  Table 1. Group characteristics at baseline    
 NAFLD (n=11)    Controls (n=14) 
Age y (range) 59 (49-64) 54 (41-65) 
Body weight kg 90.0±2.2 (75.6-102.4)                 89.7±2.4 (78.3-107.9)         
BMI kg/m2 28.9±0.3 (26.9-30.8) 28.4±0.5 (26.0-31.0) 
Waist circumference cm 104±2 (93-113) 104±1 (100-114) 
Liver fat % 17.2±2.7b (7.9-36.8) 2.5±0.3 (0.5-4.6) 
Triacylglycerol mmol/l 1.89±0.27a (1.10-4.01) 1.33±0.23 (0.60-3.80) 
Cholesterol mmol/l 5.91±0.25 (4.60-7.20) 5.51±0.28 (4.30-7.20) 
HDL cholesterol mmol/l 1.22±0.08 (1.00-2.00) 1.24±0.08 (0.90-2.10) 
Glucose mmol/l 5.73±0.11 (4.90-6.10) 5.46±0.12 (4.90-6.40) 
Systolic BP mmHg 131±7  (113-177) 134±3 (110-156) 
Diastolic BP mmHg 86±4.5 (67-113) 84±2.7 (62-93) 
 





    Table 2.  Effects of high and low sugars diets on anthropometrics and plasma lipids 
           NAFLD (n=11)        Controls (n=14) 
 High sugars Low sugars High sugars Low sugars 
Body weight (kg) 89.8±2.5 87.7±2.4c 88.9±2.8 86.7±2.9b 
BMI (kg/m2) 28.8±0.4 28.2±0.5 28.1±0.6 27.4±0.6 
Liver fat %1 





  3.6±1.3 
24.8±0.7 
  1.5±0.3 
23.8±0.9 
Plasma TAG3 mmol/l 2.05±0.24a 1.77±0.22 1.33±0.15 1.13±0.08 
Plasma cholesterol 
mmol/l 
5.59±0.33 5.24±0.30 5.10±0.25 4.82±0.26 
Plasma LDL-C mmol/l 3.40±0.26 3.23±0.28 3.27±0.19 3.13±0.21 
Plasma HDL-C 
mmol/l 
1.21±0.09 1.15±0.07 1.19±0.07 1.16±0.08 
Plasma glucose 
mmol/l 
5.35±0.09 5.39±0.09 5.08±0.11 5.11±0.08 
Plasma insulin mU/l 21.2±2.6 21.4±1.0 17.9±1.4 17.7±2.4 
HOMA2-IR 2.72±0.33 2.76±0.12 2.28±0.17 2.26±0.29 
 
Values are arithmetic means ± SEMs unless stated otherwise. 1Measured by MRS on 
subgroup n=17. 2Measured by bio-electric impedance. 3Geometric mean ± SEM. Significant 
difference between groups (within diet) aP <0.02. Significant difference between diets 




                                       
 
Table 3:  Effects of high and low sugars diets on plasma lipoprotein fraction concentrations  
 NAFLD (n=11)         Controls (n=14) 
 High sugars Low Sugars  High sugars Low Sugars  















IDL-TAG μmol/l   61±5   52±5   54±5   65±11 










VLDL2-Chol μmol/l 163±45   97±13   82±10   80±13 
IDL-chol μmol/l 167±53   88±13   88±11   99±16 
VLDL1-apoB mg/l 15.6±2.5 17.4±3.0 15.1±2.6 11.5±1.9 
VLDL2-apoB mg/l 12.5±2.1 11.6±1.5 13.1±3.4 11.0±2.7 
IDL-apoB mg/l 21.9±4.6 14.1±1.8e 20.2±5.0 20.9±5.8 
LDL-TAG  μmol/l  
LDL2-TAG μmol/l 
1231±165b 
    99±10 
1088±130c 
    93±13 
843±71 
   75±12 
 705±57 
    71±8 
LDL3-TAG μmol/l     79±12      72±8     60±7     65±6 
LDL2-chol μmol/l 1019±87   931±106   781±95   881±82 
LDL3-chol μmol/l 1222±68 1252±60 1141±94 1172±45 
LDL2-apoB mg/l   306±53   255±40   258±33   249±32 
LDL3-apoB mg/l   567±92   574±98   570±48   459±53 
Small dense LDL μmol/l 1459±210 1228±175a 1043±112   848±78 
Values are mean ± SEM. Significant difference between groups (within diet) aP<0.05; 
bP<0.02; cP<0.005; dP<0.001. Significant difference between diets (within group) eP<0.05. 
All differences were adjusted for body weight. 1Sum of VLDL1 and VLDL2 –TAG. 
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          Table 4: Effects of high and low sugars diets on lipoprotein kinetics and DNL 
      NAFLD (n=11)    Controls (n=14) 
 High sugars Low Sugars  High sugars Low Sugars  
VLDL1-TAG production rate g/d 









VLDL2-TAG production rate g/d 4.90±0.59 3.70±0.43d 3.63±0.27 3.98±0.43 
VLDL2-TAG FCR pools/d 11.5±1.1 12.2±1.3 13.1±1.0 14.3±0.9 
VLDL1-apoB production rate mg/d 481±76 492±58 546±56 414±54 
VLDL1-apoB FCR pools/d 9.0±1.0 10.8±2.2 14.7±2.7 13.4±2.4 
VLDL2-apoB production rate mg/d 546±176 498±164 720±310 647±212 
VLDL2-apoB FCR pools/d 12.5±2.8 12.8±2.4 13.6±1.9 14.9±1.6 
IDL-apoB production rate mg/d 609±122 391±69f 740±159 737±213 
IDL-apoB FCR pools/d 9.5±1.9 8.7±0.9 12.2±1.1 12.1±1.2 
LDL2-apoB production rate mg/d 1452±277 858±101 1075±109 1176±118 
LDL2-apoB FCR pools/d 1.59±0.25 1.35±0.23 1.59±0.24 1.74±0.26 
LDL3-apoB production rate mg/d 2069±388 942±278 1518±237 1374±273 
LDL3-apoB FCR pools/d 
Contribution of DNL to:                 
VLDL1-TAG production g/d          
VLDL2-TAG production g/d                       















Values are mean ± SEM. Significant differences between groups (within diet) aP=0.01; 
bP<0.05, cP=0.003. Significant differences between diets (within group) dP=0.036; eP=0.02; 
fP=0.06. All differences were adjusted for body weight. For the IDL and LDL2 kinetic data 
NAFLD (n=9), and n=8 for the LDL3 kinetic data due to insufficient data for the model fit.  
1Analysed for first period only, so between group comparisons (within diet) only were 





Table 5.   Effects of high and low sugars diets on palmitate kinetics, post-heparin 
lipase activities, and plasma apoproteins 
 
      NAFLD (n=11)     Controls (n=14) 
 High sugars Low Sugars  High sugars Low Sugars  
Plasma NEFA  μmol/l 658±30c 548±44 438±31 526±42a 
Plasma Palmitate  μmol/l 220±39 238±25 214±25 218±28 
Palmitate production rate  μmol/min 169±11 147±12d 168±15 168±17 
Palmitate MCR  ml/min 863±74 647±56e 863±110 850±101 
Post heparin LPL  pmol/ml/min 1.33±0.31 1.30±0.21 1.36±0.19 1.97±0.32 
Post heparin HL  pmol/ml/min 2.13±0.48a 1.43±0.38 1.01±0.17 0.90±0.18 
Plasma apoE  mg/l 33.3±3.7 30.2±2.7 29.1±1.4 27.7±1.4 
Plasma apoC-III  mg/l 112.2±9.8a 103.8±9.1b  86.0±7.5 73.5±5.4  
Plasma apoC-II  mg/l  82.7±9.2 77.0±8.0a 61.7±6.1 56.9±5.6 
 
Values are mean ± SEM. Significant difference between groups (within diet); aP<0.05; 
bP<0.01; cP<0.001. Significant difference between diets (within group); dP<0.05; eP<0.01. 













Figure legends                                                   
Figure 1  
Effects of high and low sugar diets (black and white bars, respectively) in men with NAFLD 
and low liver fat controls on the plasma concentrations of: a) VLDL1-TAG, and b) VLDL2-
TAG. Effects of high and low sugar diets on the contribution of fatty acids from systemic 
(black bars), splanchnic (white bars) and DNL (grey bars) to: c) VLDL1-TAG production rate 
and  d) VLDL2-TAG production rate.  Significance of weight-adjusted differences between 
groups and diets are as shown, and for differences between groups; P<0.05; **P=0.006; 
***P=0.003.  #P=0.08 denotes trend for difference between diets in controls. 
 
Figure 2  
Summary schematic of the relative effects of a high and low sugar diet (red hatched arrows) 
on lipoprotein metabolism in men with NAFLD and low liver fat controls. Thickness of black 
arrows represents the magnitude of pathway in men with NAFLD relative to controls (PR = 
production rate, FCR = fractional catabolic rate). *Significance of increases in liver fat in 
both NAFLD and controls, after the high sugar diet relative to the low sugar diet, were not 
maintained after adjustment for body weight.   
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Dietary exchange model 
The sugar content of the two diets was achieved by a dietary exchange of sugar for starch using 
foods that were either high or low in total sugars (≥ 40% or ≤ 10% of total carbohydrate (CHO), 
respectively).  Foods with intermediate sugar content were excluded from the dietary exchange 
model, the aim of which was to replace two thirds of the habitual CHO intake with study foods 
(approximately 180 g/day) without changing other dietary components. Participants were 
required to exchange 6 portions of their habitual CHO per day (a portion representing 30g 
CHO) with either the high or low sugar foods, depending on their allocated diet. A number of 
different foods and drinks (containing either high sugar/low starch or low sugar/high starch) 
were supplied to the participants, which allowed dietary flexibility and aided compliance. The 
intervention diets were designed to be matched for total carbohydrate, protein and fat content 
and iso-energetic. Five home visits were made every 2 weeks to supply study foods, measure 
body weight, and to assess daily food and drink portion sheets to help maintain dietary 
compliance, and to maintain body weight to within ± 0.5 kg.  
                                          Figure 1: Protocol for metabolic study 
 




Data analysis (Sources of fatty acids for VLDL production) 
Palmitate production rate (PR) was calculated as: Palmitate PR (µmol/min) = Infusion rate 
of palmitate tracer (µmol/min) /TTRSS.  Where TTR = m/z 286/270 at time t minus m/z 
286/270 at t=0 min, TTRSS = mean TTR (t=420-480 min) and SS= steady state. 
The contribution of circulating palmitate (systemic contribution) to VLDL1-TAG PR was 
calculated as:  Systemic contribution of fatty acids to VLDL1-TAG PR (g/d) =VLDL1-TAG 
PR (g/d) x ((VLDL1 TAG palmitate TTRSS / plasma palmitate TTRSS). This will include a 
contribution from visceral fat, since some labelled palmitate will be taken-up by this fat store 
and released into the portal vein. 
The percent contribution of hepatic DNL-derived palmitate to VLDL1 and VLDL2-TAG PR 
was calculated from the deuterium enrichment in the palmitate of VLDL1 and VLDL2-TAG 
and in plasma water as previously described [1]. The calculation assumes that in all VLDL-
TAG fatty acids derived from DNL, the enrichment in TG-palmitate (Maximum palmitate 
TTR) will be Maximum palmitate TTR = 2H2O TTR x N, where 
2H2O TTR is the 
enrichment of the plasma water, and N is the maximum number of deuterium atoms, that can 
be incorporated into a molecule of palmitate. In the present study N was 21, based on 
previous observations [1]. The percentage of palmitate derived from DNL in VLDL-TAG 
was calculated as: % hepatic DNL in VLDL-TAG palmitate = (VLDL-TG palmitate TTR / 
maximum palmitate TTR) / 100 where TTR is m/z 271/270 at time 12 hour minus 271/270 at 
time 0 minutes. For details of the time course of deuterium incorporation into VLDL-TAG 
palmitate see Diraison et al. (1997) [2]. 
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The contribution of DNL to VLDL1-TAG PR was estimated as:  DNL contribution to 
VLDL1-TAG PR (g/d) = % hepatic DNL x VLDL1-TAG PR (g/d) x 100.   
The splanchnic fat contribution was assumed to be all other sources of fatty acids and was 
calculated as:  Splanchnic fat contribution of fatty acids to VLDL1-TAG PR (g/d) = VLDL1-
TAG PR (g/d) - (DNL (g/d) + Systemic (g/d)).                                                                                           
In these calculations it was assumed that palmitate is a representative of NEFAs.  VLDL2-
TAG PR was substituted for VLDL1-TAG PR in the above equations to calculate the 
contribution of different fatty acid sources to VLDL2-TAG PR.   
 Kinetic modelling of VLDL1 and VLDL2-TAG                                                                                         
VLDL1-TAG and VLDL2-TAG FCR were calculated using a compartment model of VLDL1-
TG and VLDL2-TG kinetics using SAAM II software. The model represents the kinetics of 
the tracer-to-tracee ratio (TTR) profiles which change as labelled glycerol is removed from 
plasma and incorporated into the TAG fractions. Plasma glycerol kinetics was described by a 
sum of three exponentials representing a three compartment model. A five-compartment 
chain described a time delay due to synthesis and secretion of VLDL1 and VLDL2-TAG. The 
model is schematically depicted in Fig. 2. 
 
Figure 2. Schematic of model used to describe TTRs of VLDL1 and VLDL2-TAG. 
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The model assumes steady state of native (unlabelled) glycerol throughout the experimental 
period, i.e. a constant appearance, disappearance, and incorporation of native glycerol into the 
TAG fractions. The incorporation of glycerol into VLDL by the liver is subject to a delay. The 
model included a compartment for VLDL1-TAG and a compartment for VLDL2-TAG with an 
input into both compartments from the glycerol precursor pool, a loss from each compartment 
and a transfer from the VLDL1-TAG compartment to the VLDL2-TAG compartment. VLDL1-
TAG and VLDL2-TAG production rates were calculated as the product of VLDL1-TAG and 
VLDL2-TAG FCR and their respective TAG pools. VLDL1 and VLDL2-TAG pools were 
calculated from VLDL1 and VLDL2-TAG concentration and plasma volume which was 
determined by the method of Pearson et al [2].  
Kinetic modelling of apoB 
VLDL1, VLDL2, IDL, LDL2 and LDL3 apoB FCR and production rate were determined using 
a multi-compartmental model using SAAM II software which incorporated a forcing function 
corresponding to precursor (α-KIC) enrichment and a delay function accounting for the amount 
of time required for synthesis and production rate of VLDL1 and VLDL2-apoB. Similar to the 
TAG model, a delay compartment consisting of a five-compartment chain was added to 
account for time required for the synthesis and secretion of VLDL1 and VLDL2-apoB. The 
model is schematically depicted in Figure 3. Production rate (mg/day) was calculated as the 
product of FCR and the apoB pool size. ApoB pool size (mg) was calculated as the product of 















Figure 3. Schematic description of the model used to describe TTRs of VLDL1 VLDL2, 
IDL, LDL2 and LDL3-apoB. 
In both models, the parameters were estimated using the weighted non-linear regression 
analysis. The weights were reciprocal to the variance of the measurement error. The 
measurement error was assumed uncorrelated with zero mean; a constant standard deviation of 
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                                    Table 1.  Intake of energy and macronutrients  
                                         NAFLD (n=11)             Controls (n=14) 
 High sugar Low sugar High sugar Low sugar 
Total energy MJ/d 10.6±8.6 9.6±6.2 10.6±5.5 10.1±4.3 
Carbohydrate g/d 311±22 240±14 342±20 270±18 
% energy 50±2 42±2a 54±2 44±2b 
Total sugars g/d 168±15 53±6b 177±14 58±6b 
% energy 27±2 9±1b 28±2 10±1b 
Starch g/d 143±10 187±9a 165±11 212±14a 
% energy 23±1 33±2b 26±1 35±1b 
NMES g/d 152±13 31±2b 164±15 33±4b 
% energy 25±2 6±0.4 26±2 5±0.5 
Protein g/d 92±9 98±10 92±5 96±5 
% energy 15±1 17±1 15±1 16±1 
Total fat g/d 81±13 86±10 75±6 92±5 
% energy 28±3 33±2 26±2 34±1b 
SFA g/d 34±6 36±6 27±3 35±3 
Fibre g/d 21±2 23±3 21±2 25±2 
Sodium g/d 3.0±0.4 3.5±0.3 2.8±0.2 3.9±0.3b 





   
 
 
                Table 2.  Body fat distribution measured by MRS  
 
 
 NAFLD (n=7) Controls (n=10) 
 High sugar Low sugar High sugar Low sugar 
Total body fat 
(kg)  




17.6±0.8 16.7±0.8 17.6±1.7 16.6±1.8 
Total internal fat 
(kg) 
9.0±0.9 8.0±0.5 7.3±0.5 6.6±0.8 
Abdominal sub-
cutaneous fat (kg) 
5.2±0.5 4.8±0.3 5.2±0.7 4.8±0.7 
Peripheral sub-
cutaneous fat (kg) 
12.4±0.6 11.9±0.3 12.4±1.0 11.8±1.2 
Visceral fat (kg) 4.6±0.4 4.8±0.4 4.0±0.3 3.6±0.5 
Non-visceral 
internal fat (kg) 
4.4±0.9 3.2±0.2 3.3±0.3 3.0±0.3 
  
           Values are mean ± SEM 
 
